Interviewer: Dr. Levin, your team at Xelyra Biotech recently published some fascinating in silico data on Lipo405. Can you explain what that means?

Dr. Levin: Of course. In simple terms, we used a powerful computer simulation to predict how the Lipo405 formula would affect key aging processes in the body. It’s a way to test our hypothesis using vast amounts of existing biological data before starting a full human study.

Interviewer: And what was the most significant prediction from this simulation?

Dr. Levin: We were most encouraged by the dual-action effect. On one hand, the model predicts an 18% reduction in a key biomarker for senescent “zombie” cells. These are cells that create a lot of inflammatory noise as we age. On the other hand, it showed a 23% increase in the activity of NK cells, which are the immune cells that naturally clear out those very zombie cells.

Interviewer: So it’s a two-pronged approach?

Dr. Levin: Exactly. It’s not just about defense. The formula is designed to simultaneously reduce the burden of dysfunctional cells while strengthening the very system meant to handle them. It’s a holistic approach that targets a root cause of age-related decline, rather than just the symptoms.